These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16160166)

  • 1. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope.
    Raviv Y; Viard M; Bess JW; Chertova E; Blumenthal R
    J Virol; 2005 Oct; 79(19):12394-400. PubMed ID: 16160166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine.
    Arthur LO; Bess JW; Chertova EN; Rossio JL; Esser MT; Benveniste RE; Henderson LE; Lifson JD
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S311-9. PubMed ID: 9814959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.
    Raviv Y; Blumenthal R; Tompkins SM; Humberd J; Hogan RJ; Viard M
    J Virol; 2008 May; 82(9):4612-9. PubMed ID: 18305038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type 1.
    Belanger JM; Raviv Y; Viard M; Jason de la Cruz M; Nagashima K; Blumenthal R
    Photochem Photobiol; 2010; 86(5):1099-108. PubMed ID: 20630026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide.
    Sharma A; Raviv Y; Puri A; Viard M; Blumenthal R; Maheshwari RK
    Biochem Biophys Res Commun; 2007 Jun; 358(2):392-8. PubMed ID: 17493582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of non-enveloped virus by 1,5 iodonaphthyl azide.
    Gupta P; Sharma A; Mathias V; Raviv Y; Blumenthal R; Maheshwari RK
    BMC Res Notes; 2015 Feb; 8():44. PubMed ID: 25879201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.
    Javaherian K; Langlois AJ; Montefiori DC; Kent KA; Ryan KA; Wyman PD; Stott J; Bolognesi DP; Murphey-Corb M; Larosa GJ
    J Virol; 1994 Apr; 68(4):2624-31. PubMed ID: 7511176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
    Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
    J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent.
    Warfield KL; Swenson DL; Olinger GG; Kalina WV; Viard M; Aitichou M; Chi X; Ibrahim S; Blumenthal R; Raviv Y; Bavari S; Aman MJ
    J Infect Dis; 2007 Nov; 196 Suppl 2():S276-83. PubMed ID: 17940961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins.
    Chertova E; Crise BJ; Morcock DR; Bess JW; Henderson LE; Lifson JD
    Curr Mol Med; 2003 May; 3(3):265-72. PubMed ID: 12699362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins.
    Morcock DR; Thomas JA; Gagliardi TD; Gorelick RJ; Roser JD; Chertova EN; Bess JW; Ott DE; Sattentau QJ; Frank I; Pope M; Lifson JD; Henderson LE; Crise BJ
    J Virol; 2005 Feb; 79(3):1533-42. PubMed ID: 15650179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.
    Rossio JL; Esser MT; Suryanarayana K; Schneider DK; Bess JW; Vasquez GM; Wiltrout TA; Chertova E; Grimes MK; Sattentau Q; Arthur LO; Henderson LE; Lifson JD
    J Virol; 1998 Oct; 72(10):7992-8001. PubMed ID: 9733838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts.
    Graham DR; Chertova E; Hilburn JM; Arthur LO; Hildreth JE
    J Virol; 2003 Aug; 77(15):8237-48. PubMed ID: 12857892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys.
    Balzarini J; Naesens L; Slachmuylders J; Niphuis H; Rosenberg I; Holý A; Schellekens H; De Clercq E
    AIDS; 1991 Jan; 5(1):21-8. PubMed ID: 2059358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
    Li A; Baba TW; Sodroski J; Zolla-Pazner S; Gorny MK; Robinson J; Posner MR; Katinger H; Barbas CF; Burton DR; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 1997 May; 13(8):647-56. PubMed ID: 9168233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins.
    Lifson JD; Rossio JL; Piatak M; Bess J; Chertova E; Schneider DK; Coalter VJ; Poore B; Kiser RF; Imming RJ; Scarzello AJ; Henderson LE; Alvord WG; Hirsch VM; Benveniste RE; Arthur LO
    AIDS Res Hum Retroviruses; 2004 Jul; 20(7):772-87. PubMed ID: 15307924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins.
    Hill CM; Kwon D; Jones M; Davis CB; Marmon S; Daugherty BL; DeMartino JA; Springer MS; Unutmaz D; Littman DR
    Virology; 1998 Sep; 248(2):357-71. PubMed ID: 9721244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative measurement of fusion of HIV-1 and SIV with cultured cells using photosensitized labeling.
    Raviv Y; Viard M; Bess J; Blumenthal R
    Virology; 2002 Feb; 293(2):243-51. PubMed ID: 11886244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
    Javaherian K; Langlois AJ; Schmidt S; Kaufmann M; Cates N; Langedijk JP; Meloen RH; Desrosiers RC; Burns DP; Bolognesi DP
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1418-22. PubMed ID: 1371358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.